Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia May 13, 2024
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting April 24, 2024
Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization January 5, 2024
Be Bio Announces New Preclinical Data Demonstrating its Novel Engineered B Cell Medicine (BCM), BE-101, Produces Active and Sustained Levels of Factor IX for the Treatment of Hemophilia B December 11, 2023
Be Biopharma Presents Preclinical Data Demonstrating Ex-Vivo Engineered B Cell Medicines Produce Highly Active and Sustained Levels of Antitumor Biologics November 1, 2023
